ArticleThe journal of headache and pain2023
Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019.
Article in The journal of headache and pain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.The journal of headache and pain · 2026Trial
- Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.The journal of headache and pain · 2024Trial
- Trial
- Integrating Genetics With Epidemiological Measurements Identifies Burden QTLs of Inflammatory Bowel Disease across 20 Countries.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- [Gender differences in children and adolescents with migraine].Schmerz (Berlin, Germany) · 2026Review
- Screening for Mild Vertebral Artery Dissection Using 3-Dimensional T1-weighted Black-blood Magnetic Resonance Imaging: A Retrospective Observational Study of 3,049 Consecutive Walk-in Patients Presenting with Headache.Neurologia medico-chirurgica · 2026Observational
- The roles of microglia and astrocytes in inflammasomes and neurological disorders.Neural regeneration research · 2026Article
- Abnormal baseline brain activity in migraine without aura with versus without patent foramen ovale: a resting-state functional magnetic resonance imaging study.Neuroradiology · 2026Article
- Early life stress induces brain-wide electrical network predisposition to migraine.The journal of headache and pain · 2026Article
- Current landscape of migraine care with expert consensus from East Asia.The journal of headache and pain · 2026Review
- Global, regional, and national burden of diabetes mellitus type 2-related chronic kidney disease from 1990 to 2021 and projections to 2040.Journal of family medicine and primary care · 2026Article
- Geriatric Migraine, Geroscience, and Sustainable Development Goals: Bridging Clinical Complexity and Public Health Priorities.Journal of clinical medicine · 2026Review
- Gut microbiota dysbiosis and metabolic reprogramming in pediatric migraine: a multi-omics analysis revealing diagnostic biomarkers.The journal of headache and pain · 2026Article
- Article
- Trends in self-reported headache disorder in Spain between 2006 and 2023: the role of sociodemographic factors.BMC public health · 2026Article
- Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study.Pain and therapy · 2026Article
- Global, regional, and national burden and future projections of pancreatitis: A Joinpoint, APC, and ARIMA modeling analysis.Clinical and experimental medicine · 2026Article
- Lifetime Probability of Developing Migraine: A Novel Epidemiological Perspective Based on Global Burden of Disease Data.Pain research & management · 2026Article
- Post Hoc Subgroup Analyses of the Efficacy and Safety of Zavegepant for the Acute Treatment of Migraine According to Baseline Triptan Experience.Journal of pain research · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe majority of epidemiological studies on migraine have been conducted in a specific country or region, and there is a lack of globally comparable data. We aim to report the latest information on global migraine incidence overview trends from 1990 to 2019.
methodsIn this study, the available data were obtained from the Global Burden of Disease 2019. We present temporal trends in migraine for the world and its 204 countries and territories over the past 30 years. Meanwhile, an age-period-cohort model be used to estimate net drifts (overall annual percentage change), local drifts (annual percentage change in each age group), longitudinal age curves (expected longitudinal age-specific rate), and period (cohort) relative risks.
resultsIn 2019, the global incidence of migraine increased to 87.6 million (95% UI: 76.6, 98.7), with an increase of 40.1% compared to 1990. India, China, United States of America, and Indonesia had the highest number of incidences, accounting for 43.6% of incidences globally. Females experienced a higher incidence than males, the highest incidence rate was observed in the 10-14 age group. However, there was a gradual transition in the age distribution of incidence from teenagers to middle-aged populations. The net drift of incidence rate ranged from 3.45% (95% CI: 2.38, 4.54) in high-middle Socio-demographic Index (SDI) regions to -4.02% (95% CI: -4.79, -3.18) in low SDI regions, 9 of 204 countries showed increasing trends (net drifts and its 95% CI were > 0) in incidence rate. The age-period-cohort analysis results showed that the relative risk of incidence rate generally showed unfavorable trends over time and in successively birth cohorts among high-, high-middle-, and middle SDI regions, but low-middle- and low-SDI regions keep stable.
conclusionsMigraine is still an important contributor to the global burden of neurological disorders worldwide. Temporal trends in migraine incidence are not commensurate with socioeconomic development and vary widely across countries. Both sexes and all age groups should get healthcare to address the growing migraine population, especially adolescents and females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.